Townsquare Capital LLC Acquires New Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Townsquare Capital LLC purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 12,386 shares of the medical equipment provider’s stock, valued at approximately $1,108,000.

Several other institutional investors and hedge funds have also modified their holdings of LNTH. Wilmington Savings Fund Society FSB bought a new position in Lantheus during the third quarter valued at about $25,000. Kestra Investment Management LLC bought a new position in shares of Lantheus in the 4th quarter valued at approximately $27,000. Summit Securities Group LLC bought a new position in shares of Lantheus in the 4th quarter valued at approximately $37,000. UMB Bank n.a. lifted its holdings in Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after purchasing an additional 134 shares during the last quarter. Finally, World Investment Advisors LLC acquired a new position in Lantheus during the third quarter valued at approximately $60,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

LNTH has been the subject of several recent analyst reports. JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. B. Riley dropped their price objective on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a report on Friday, March 21st. Finally, Truist Financial lifted their target price on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Lantheus currently has a consensus rating of “Moderate Buy” and an average price target of $129.43.

Insider Activity

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares of the company’s stock, valued at $11,445,207.20. This trade represents a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares of the company’s stock, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 63,109 shares of company stock worth $6,016,046. 1.50% of the stock is owned by corporate insiders.

Lantheus Price Performance

Lantheus stock opened at $101.32 on Friday. The business has a 50 day simple moving average of $95.00 and a 200 day simple moving average of $95.55. Lantheus Holdings, Inc. has a one year low of $61.47 and a one year high of $126.89. The company has a market capitalization of $6.94 billion, a PE ratio of 16.86 and a beta of 0.20.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.